Long-term contraception with a single implant of the progestin ST-1435.
Silastic capsules containing the synthetic progestin ST-1435 was inserted in 282 women of reproductive age who desired long-term contraception. Each woman received a single implant for 6 months' use. After evaluating the experience of the first 45 subjects, replacement capsules were offered to women desirous of continuing the method after the initial 6 months of use. In the first 6-month segment one pregnancy and 1720 woman-months of use were recorded. The total experience, through as many as six segments of use was 3373 woman-months of use and one pregnancy. The Pearl Index is 0.36 per 100 woman-years. The single pregnancy, recorded in the 1st month of the first segment, may represent a conception prior to implant placement. Amenorrhea was the most common side effect reported, with 83% of the women having at least one nonbleeding interval longer than 60 days during the first segment of use.
D000568:Amenorrhea / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004343:Drug Implants; D005260:Female; D006801:Humans; D009652:Norpregnenes / Q000008:administration & dosage*; D009653:Norprogesterones / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
D004343:Drug Implants; D009652:Norpregnenes; D009653:Norprogesterones; D045167:Progesterone Congeners; C029167:ST 1435